Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38.
Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38.
guardant health股票價格上漲，因該公司推出新的Guardant360 TissueNext檢測。此外，Canaccord Genuity保持買入評級，並將目標價提高至38美元。
Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38.
guardant health股價上漲，公司發佈了新的Guardant360 TissueNext檢測。此外，Canaccord Genuity維持買入評級，並將其價格目標提高至38美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。